Hema Now
Daniel DeAngelo, Chief of the Division of Leukemia, Dana-Farber Cancer Institute; and Professor of Medicine, Harvard Medical School, Boston, Massachusetts, USA, discusses advances in leukaemia treatment, precision medicine, targeted therapies, immunotherapy, and minimal residual disease, alongside the challenges of translating promising treatments into practice and improving access to clinical trials.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Daniel DeAngelo is Chief of the Division of Leukemia at the Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School, Boston, Massachusetts, USA. His clinical and research work focuses on adult leukaemias, targeted therapies, and innovative clinical trials.
Timestamps:
00:00 – Introduction
01:05 – Career and Leukaemia
02:55 – Advances in Leukaemia Treatment
04:45 – Molecular Drivers and Precision Medicine
07:00 – Next Generation Targeted Therapies
09:00 – Immunotherapy in Acute Leukaemias
12:00 – Minimal Residual Disease Assessment
14:20 – Translating Therapies into Practice
16:00 – Improving Clinical Trial Access
18:30 – Three Wishes for Haematology
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Keywords: Keywords: Immunotherapy, leukaemia, precision medicine, targeted therapies.
